bluuebunny/crossref_metadata_2025_split huggingface dataset:
PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform.
Authors: Basterretxea Laura , Hernandez Amaia , Gurruchaga Ibon , Gomez Mediavilla Borja , Linares Espinos Estefania , Esteban Brigida , Cacho Diego , Congregado Belen , Rivero Belenchon Ines , Sancho Gemma , Lainez Nuria , Buchser David , Sanguedolce Francesco , Lashey Matthew , Duran Ignacio 
Published: June 2024

e23190 Background: It is well established that the monitoring and evaluation of PROs in cancer patients has a positive impact in both quality of life and overall survival [Basch E., JAMA 2017]. In parallel, the widespread use of electronic devices such as smart phones in the general population have increased significantly over recent years [Statista, 2023], representing a unique opportunity to operationalize ePROs. However, there is uncertainty about the feasibility and applicability of these technologies in certain patient population such as prostate cancer (PC) patients. PRO-WAVE1 aims to determine the acceptability and engagement of the Wave Health patient app and healthcare provider portal, enhanced for PC patients. Specific endpoints include measuring longitudinal use of varying ePROs to impact care management, patient health literacy, and ability to identify and manage emerging risks. Methods: Patients across eight sites in Spain engaged with the Wave Health App over a 13-week period. Each week, patients completed a validated weekly symptom review (WSR) assessing 16 Prostate cancer-specific symptoms, including severity and/or frequency of each; as well as a health-related QoL (FACT-P) and health literacy survey (CHLT-30-Dkspa). A report summary of the patients’ WSR was generated for care team view in the Wave Health Connect platform – specifically to conduct weekly check ins on patients, including verifying patient completion; evaluating report content; indicating plans for follow up per patient; and rating their perceived value of the platform. Results: 98 patients were enrolled in the study – of which 82 actively participated in the study (84% acceptance). The compliance rate for the ePRO questionnaires was 93.3%, while during their participation, patients used the app for an average of 12.2 weeks, and approximately two-thirds (67.4%) used the app for all 13 weeks. Patient satisfaction with the platform was 93%, with 100% of respondents feeling the information provided in the app was relevant to their personal experience. Correspondingly, almost all HCPs (98%) rated the platform as useful – with the majority willing to recommend it to their peers and future patients; 90% of HCPs positively perceived the platform’s impact on the quality of communication with patients. Conclusions: Study results exceeded expectations for patient acceptability and engagement with the app; as well as perceived usefulness of the portal among HCPs – suggesting the platform as an impactful tool for patients working with HCPs to manage treatment journeys. A larger study using a comparator arm will help further evaluate the impact on costs and clinical outcomes.
Impact of multidisciplinary tumor boards on clinical decision making in a genitourinary oncology clinic in Mexico city.
Authors: Seidman Sorsby Alec , Caballero Rosa , Rivera Fernanda Estefanía , Remolina Bonilla Yuly Andrea , Vazquez-Narváez Karina G. , Vazquez-Manjarrez Sara E. , Flores Balcázar Christian Haydeé , Castillejos-Molina Ricardo A. , Rodriguez-Covarrubias Francisco , Bourlon Maria T. 
Published: June 2024

e23217 Background: Effective management of genitourinary neoplasms demands a comprehensive approach due to the diverse treatment options and the need for multiple specialists. Multidisciplinary tumor board (MDTB) meetings are a platform for experts to collectively assess and discuss the latest evidence and provide their expertise to tailor treatment plans for patients. Methods: Cases discussed during uro-oncology MDTB meetings at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City over a five-year period (01/2018 to 12/2022) were included. We analyzed the type of neoplasm, reason for case discussion, specialties involved and whether the final decision led to a modification of the original plan. Descriptive statistics were used for analysis. Chi-squared test was used to determinate differences and p value < 0.05 was considered statistically significant. A logistic regression analysis was performed for multivariate analysis. Results: Over the study period, 500 discussions involving 399 patients were included. 87% were men. Prostate, kidney, testicular, upper tract urothelial and bladder carcinoma, represented: 223 (44.6%), 117 (23.4%), 84 (16.8%), 37 (7.4%), 32 (6.4%) of cases, respectively. The majority were presented by urology (319 cases; 63.6%). The primary reason for presentation was surgical decisions in 54.6%. Regarding final conclusions, 55.8% underwent modifications in the treatment plan, 33.2% had no changes and 11% remained inconclusive, requiring further assessment. Individuals with metastatic disease had a higher likelihood of treatment plan changes in 61.6% vs 52.3% (OR 1.46 95%CI 1.01-2.12; p = 0.042). The 163 cases (32.6%) presented during the COVID-19 pandemic were more prone to have treatment modifications 62.6% vs 52.5% (OR 1.51 95%CI 1.03-2.22; p = 0.034); cases presented for surgical reasons during this period were more likely to have a change in treatment modality 74% vs 52.3% (OR 2.6 95%CI 1.34-5.04; p = 0.004). Implementation of results was successful in most cases (72%), with a median time of 3.6 weeks. Reasons for not implementing the plan included: patient decision, treating physician decision, comorbidities, death, and lack of resources. Factors associated with implementation in the multivariate analysis included: male gender (OR 2.81), cases presented during pandemic (OR 2.0), and by urology service (OR 1.92). Conclusions: Among patients presented in our uro-oncology MDTB meetings, more than half will have a change in the original treatment plan, and this agreed strategy is successfully implemented in most individuals. These sessions remained key for patient management during the COVID-19 pandemic.
Adherence to fertility preservation guidelines in young patients with breast cancer: A retrospective analysis.
Authors: Gonzalez-Gonzalez Luisa F. , Baylon Valdez Victor , Zamudio Lozoya Enrique Jose , Ochoa-Elizondo Patricio , Mendoza-Muraira Paolo , Martinez-Garcia Lascurain Regina , Martinez-Sanciprian Rafael , Bates Rodriguez Valeria , Mares García América Susana , Reza Bravo Gustavo Gil , Gonzalez Mendoza Rene Lazaro 
Published: June 2024

e23255 Background: Breast cancer affects a considerable proportion of women of childbearing age making it important to provide options for fertility preservation. At Chihuahua's State Cancer Center, a state-federal-funded institution providing free oncological care, and ensuring access to fertility preservation measures is integral to the multidisciplinary approach for young cancer survivors. Recognizing chemotherapy's impact on fertility, implementing fertility preservation measures is key. Assessing adherence to these guidelines is essential for comprehensive care and holistic well-being in young breast cancer patients at our center. Methods: In this retrospective study at the Chihuahua´s State Cancer Center, we examined adherence to fertility preservation guidelines among breast cancer patients aged 18 to 40 years. The primary method used for fertility preservation was the administration of GnRH analogs, such as triptorelin and goserelin. Data on GnRH analog use, chemotherapy regimens, and patient demographics were collected from medical records. The study aimed to assess the integration of fertility preservation measures, particularly GnRH analogs, into treatment plans for young breast cancer patients. Additionally, we aimed to identify barriers to accessing fertility preservation services in this population. Results: The study findings revealed that out of the 749 registered breast cancer patients, 95 (12.6%) were 40 years old or younger. Among these, 75 (79%) received adjuvant and/or neoadjuvant chemotherapy, with 58 (77.3%) being in locally advanced clinical stages. Of the 75 patients who underwent chemotherapy, 20 (26.7%) also received GnRH analogs, while 55 (73.3%) did not. Among the 75 chemotherapy recipients, 16 (p = 0.046) were estrogen receptor-positive and received analogs. Furthermore, out of the 20 patients with triple-negative breast cancer, only 1 (1.3%) received an analog. Conclusions: The study indicates that GnRH analogs usage in breast cancer patients is significantly associated with estrogen receptor positivity. While estrogen receptor status is crucial for determining treatment suitability, GnRH analog utilization was notably low among triple-negative breast cancer patients. This suggests that triple-negative status alone should not preclude GnRH analog use. The findings underscore the need to raise awareness and improve adherence to ovarian suppression recommendations to enhance clinical outcomes and quality of life for breast cancer patients.
Cancer statistics: The United States vs. worldwide.
Authors: Desai Krishna , Baralo Bohdan , Kulkarni Ajinkya , Keshava Vinay E. , Iqbal Sabah , Ali Hassan , Prabhakaran Sivaguha Yadunath , Thirumaran Rajesh 
Published: June 2024

e23276 Background: Cancer is now a pandemic worldwide. Although the mortality from cancer is downtrending due to the advent of newer treatment modalities, the global burden of cancer is exponentially increasing due to early detection.Understanding the current cancer demographics can aid in developing strategies to curb the morbidity and mortality from these malignancies. Methods: The data was obtained using 2 databases: GLOBOCAN for global trends, & Surveillance, Epidemiology and End Result database Research Plus Data, 17 Registries, Nov 2022 Sub (2000-2020) for the data in the United States (US). We further stratified SEER data based on incidence, gender & median months of survival (mOS), using the Log-rank test (GraphPad Prism). Results: As per the latest GLOBOCAN analysis, 18,094,716 new cancers (51.63% males,48.36% females) & 9,894,402 deaths (55.49% males, 44.51% females) from cancer occurred, worldwide. The 5 most commonly diagnosed cancers globally were, breast (12.5%), lung (12.2%), colorectal cancer (CRC) (10.7%), prostate (7.8%), & stomach (6%). However, the 5 most common cancers causing mortality globally, were lung (18.2%), CRC (9.5%), liver (8.4%) stomach (7.8%), & breast (6.9%). Whereas, in the US, 2,281,658 new cancers (males 53.75%, females 46.24%) were detected in 2020, & 612,390 deaths (males 52.58%, females 47.41%) occurred from it. The 5 most commonly diagnosed cancers were breast (11.1%), lung (10%), prostate (9.2%), CRC (6.8%), & melanoma (4.2%). Cancer-related mortality was attributed to lung (22.6%), CRC (8.9%), pancreas (7.8%), breast (7%), & prostate (5.3%). SEER data analysis for cancer mortality in the US is listed below in Table 1. Conclusions: Analysis of 2 large databases show that the most common cancers around the world, including the US, are breast, lung, colon & prostate cancers. Breast cancer has the highest incidence, but lung cancer has the highest mortality worldwide. In the US, Whites are more affected & except breast cancer, males have a greater predeliction for the common cancers. mOS was greater for females over all. This study emphasizes the need for further analysis to introspect if modalities such as next generation sequencing-directed immunotherapy would prove beneficial in increasing overall survival. [Table: see text]
Real-world experience with fostamatinib in patients with immune thrombocytopenia: Results of an observational study (FORTE).
Authors: Goel Ruchika , Azhar Waqas , Numerof Robert P. , Chow Donna , Shah Bhavesh 
Published: June 2024

e23289 Background: Immune thrombocytopenia (ITP) is an autoantibody-mediated disease in which platelets are prematurely phagocytosed by Fcg-receptor-bearing macrophages in a spleen tyrosine kinase (SYK)-dependent signaling pathway. Corticosteroids (CS) are used to suppress the immune response, but long-term use carries a heavy burden of toxicity. Subsequent treatments for ITP include fostamatinib, a potent oral SYK inhibitor approved in 2018 based on two randomized, placebo-controlled, phase 3 trials. In trial patients, who received fostamatinib as second-line therapy following CS with or without immunoglobulins (IVIG), 25 of 32 (78%) patients achieved a platelet response of ≥50,000/µL, which was sustained for a median of 83% of treatment days. Here, we report real-world experience with fostamatinib as second-line therapy for ITP from a multi-center, prospective, observational study. Methods: The study (FORTE; NCT04904276) enrolled adult patients with ITP and an insufficient response to prior CS and/or IVIG. Patients were treated according to their clinician’s discretion, and data were collected for up to 12 months at clinic visits. Results: Sixteen patients were enrolled, and 15 were treated. Of the 15, 9 (60%) were female and the median age was 48 years (range, 20-92). 12 (80%) patients had prior CS and 6 (40%) prior IVIG. 7 (47%) patients completed the study and 8 discontinued treatment due to adverse events (4), lack of efficacy (2), and patient decision (2). After initiation of fostamatinib, 93% (14/15) of patients achieved ≥1 platelet count ≥50,000/μL. Median platelet count increased over time from 43,000/μL (IQR 19,000-105,000) at baseline to 167,000/μL (IQR 96,000-180,000) at Month 12. The median cumulative duration of elevated platelet count was 32 weeks (IQR 6.4-49.4). Concomitant CS were used by 7 (47%) patients at baseline, all of whom were able to taper as early as Month 1 and discontinue their dose by Month 3 in 4 patients, Month 6 in 2 patients, and Month 9 in 1 patient. Five patients had ITP-related AEs (4 Grade 1 and 1 Grade 2): gingival bleeding (2), mucosal haemorrhage (2), fatigue (1), contusion (3), headache (1) and epistaxis (1). There were 3 serious AEs in 2 patients: Grade 3 diarrhea in 1 and Grade 2 dyspnea and chills in 1. Overall safety results were consistent with previous studies of fostamatinib. Conclusions: Real world use of fostamatinib as documented in this observational study demonstrated efficacy and safety as second-line therapy for ITP. Fostamatinib allowed successful tapering and discontinuation of CS while maintaining platelet counts above 50,000/μL. Clinical trial information: NCT04904276 .
Mental health prevalence in Brazil: Understanding anxiety and depression in southern Capixaba region.
Authors: Aleixo Sabina B. , Pulido Jose Zago , Parmanhane Narelle , Sartoli Ana Arlete , Siller Ana Paula 
Published: June 2024

e23295 Background: The rising significance of mental health issues and psychological distress among cancer patients has prompted an in-depth investigation. In the brazilian context, this crucial aspect remains largely unexplored, with limited available data and insufficient investment in understanding the psychosocial dimensions of cancer care. This study aims to generate brazilian-specific data to facilitate the development and implementation of targeted psychosocial interventions within cancer care. Methods: From August 1, 2023, to December 31, 2023, a random selection of 263 patients at a brazilian cancer center underwent assessment for signs and symptoms of anxiety and depression using the Anxiety and Depression Assessment Scale – HAD. This validated screening scale, comprising 14 Likert-type questions, features two subscales with seven items each to track anxiety and depression symptoms. Severity scores for each subscale range from zero to 21, with higher scores indicating increased anxiety and depression levels. In this study, interviewers assessed the severity of symptoms, employing scales ranging from 0 to 21. Three score levels were identified: mild (0-7), moderate (8-11), and high (12-21). Inclusion criteria encompassed age over 18, residency in the southern region of the State of Espírito Santo, a cancer diagnosis, and active treatment. Exclusion criteria included non-residency in th southern region of th state, lack of cancer diagnosis, and oncohematological treatments. Of the 263 eligible participants, 21 were excluded for not meeting inclusion criteria, and 16 declined to participate, resulting in a final sample of 226 patients. Results: The sample comprised 160 women, with 64.90% diagnosed with breast cancer and 35.10% with other neoplasms. Among the 66 men, 41% had prostate cancer and 59% had other neoplasms. Anxiety levels in women were mild (28%), moderate (24%), and high (48%), while in men, levels were mild (39%), moderate (21%), and high (53%). Depression levels in women were mild (42%), moderate (19%), and high (39%). Notably, six suicide attempts occurred among women before cancer diagnosis, and one occurred after diagnosis. Among men, depression levels were mild (47%), moderate (22%), and high (31%). With no history of attempts of suicide in the men population. Conclusions: The study's robust dataset provides compelling and valid information, unveiling a substantial prevalence of mental disorders within the analyzed populations. It emphatically underscores the critical need for tailored supportive care in addressing the unique psychosocial challenges faced by this demographic. Furthermore, the findings advocate for the urgent implementation of targeted psychosocial support interventions to enhance the overall well-being of individuals navigating the complex terrain of cancer and its associated mental health implications.
Localized GIST in Hispanic population in North and South America.
Authors: Sarre-Lazcano Catherine , Carbajal Berenice , Rothschild Sara , Evans Denisse , Soulé Tomás , Call Jerry , Salas Rodrigo , Calderillo Ruiz German , Hernández Alondra , Luevano Castro Samuel Christopher , Alfaro Goldaracena Alejandro , Sicklick Jason K. 
Published: June 2024

e23513 Background: Most studies of gastrointestinal stromal tumors (GIST) focus upon patients in a single country. However, differences in patient presentation, treatment, and outcomes may differ between nations. We sought to compare Hispanic patients with localized GIST treated in North and South America. Methods: We performed a retrospective analysis including all Hispanic GIST patients treated at 3 tertiary referral centers in the United States (US), Mexico (MX) and Argentina (AR), as well as those enrolled by 2 patient advocacy groups in US and MX from 2000-2022. Demographic, clinicopathologic and survival data were collected and compared using Pearson’s chi-square or one-way ANOVA test. Disease-specific survival (DSS) was calculated using the Kaplan-Meier method and compared using the log-rank test. Results: Overall, 1,504 Hispanic patients (54.5% female) were analyzed. Median age at diagnosis was significantly lower in US (48 y) than MX/AR (55/57 y, p = 0.001). Presentation stage varied by country. Localized presentation was more frequent in US/MX (77%/88%) than AR (60%, p = 0.001). In 1,208 patients (80.4%) with localized disease, 97.9% underwent surgical resection. Rates of adjuvant imatinib treatment varied from 82.4%/77.0% in US/MX to 35.6% in AR (p < 0.001). Median duration of adjuvant therapy was longer in US (29 mos; range: 16-48) than MX (12 mos; range: 4-36, p < 0.001). With a median follow up of 44 mos (range: 24-78) for patients presenting with localized GIST, the estimated median DSS was 136 mos (95% CI 104-167), being significantly longer in US (267 mos, 95% CI 95-439, p = 0.02). Conclusions: While most studies of disparities focus on differences between races/ethnicities in a single country, we found that disparities also exist within similar ethnic groups across nations. Underappreciated sociopolitical determinants of health likely lead to differences in presentation, management, and long-term outcomes of Hispanic GIST patients in the Americas. Prospective cooperative studies are needed to better define barriers to care in order to improve patient outcomes in Hispanic GIST patients. [Table: see text]
Identifying intra-abdominal desmoid type fibromatosis mimicking recurrence/metastasis of GISTs using FAPI PET/CT.
Authors: Wu Chunhui , Lin Xiaojie , Wen Fang , Hu Xin , Zeng Yu , Lin Fangzeng , Sun Kaiyu , Cai Shirong , Huang Shaoqing , Zhang Xiangsong , Wang Xiaoyan , Zhang Xinhua 
Published: June 2024

e23516 Background: Intra-abdominal desmoid tumor (IADT) can mimic the recurrence/metastases of gastrointestinal stromal tumors (GISTs). However, it is difficult to radiologically differentiate IADT and recurrence/metastases of GISTs. This study aims to investigate the value of 18F fibroblast activation protein inhibitor ( [18F]FAPI-42) PET/CT in identifying intra-abdominal desmoid type fibromatosis mimicking recurrence/metastases of GISTs by comparing it to [18F]FDG PET/CT. Methods: This study retrospectively included a total of 24 patients (12 patients with IADT and 12 patients with recurrent/metastatic GISTs). The differences in [18F]FAPI-42 PET/CT parameters (SUVmax-FAPI and SUVTLR-FAPI ), [18F]FDG PET/CT parameters (SUVmax-FDG and SUVTLR-FDG), SUVfapi/SUVfdg ratio of IADT and GISTs were compared. The difference in PET/CT parameters (SUVmax, SUVTLR) of IADT between FDG PET/CT and FAPI PET/CT were compared. Immunohistochemical verification was performed on IADT lesions of all 12 patients and expression profiles of GEO datasets were analyzed to validate the FAP expression of IADT. Results: Both [18F]FAPI-42 PET/CT parameters, SUVmax-FAPI [8.8 (2.0, 16.0) vs 1.9 (1.0, 6.0), P< 0.001]and SUVTLR-FAPI [7.3 (2.0, 15.8) vs 1.7 (0.5, 6.9), P< 0.001], of IADT was significantly higher than that of GISTs, while there was no statistically significant difference in [18F]FDG PET/CT parameters, SUVmax-FDG and SUVTLR-FDG, between this two group. The ratio (SUVfapi/SUVfdg) of IADT was significantly higher than that of GISTs [3.3 (1.5, 8.0) vs 0.5 (0.1, 3.9), P= 0.001]. The SUVmax and SUVTLR of FAPI PET/CT of IADT were significantly higher than that of FDG PET/CT [8.8 (2.0, 16.0) vs 2.5 (1.1, 6.2), P< 0.001; 7.3 (2.0, 15.8) vs 0.9 (0.4, 2.7), P< 0.001; respectively]. FAP expression was found to be expressed in all the examined tissues and highly expressed in most of them. GEO database analysis shows that the FAP gene expression in DT is significantly higher than that in GISTs. Conclusions: FAPI PET/CT is a promising method in differentiating IADT from recurrence/metastases of GISTs compared with FDG PET/CT since FAP expression in DT is significantly higher than that in GISTs.